Palvella Therapeutics (PVLA) EBT Margin: 2014-2024
Historic EBT Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to 2,182.87%.
- Palvella Therapeutics' EBT Margin rose 111736.00% to 2,182.87% in Q4 2024 from the same period last year, while for Dec 2024 it was -1,833.23%, marking a year-over-year decrease of 180988.00%. This contributed to the annual value of 4,054.42% for FY2024, which is 401076.00% up from last year.
- Palvella Therapeutics' EBT Margin amounted to 2,182.87% in Q4 2024, which was down 29.12% from 3,079.55% recorded in Q3 2024.
- Palvella Therapeutics' 5-year EBT Margin high stood at 3,079.55% for Q3 2024, and its period low was -4,784.91% during Q1 2024.
- Its 3-year average for EBT Margin is -5.96%, with a median of -66.73% in 2022.
- Examining YoY changes over the last 5 years, Palvella Therapeutics' EBT Margin showed a top increase of 313,722bps in 2024 and a maximum decrease of 403,098bps in 2024.
- Quarterly analysis of 5 years shows Palvella Therapeutics' EBT Margin stood at -660.79% in 2020, then skyrocketed by 53,044bps to -130.34% in 2021, then tumbled by 6,069bps to -191.04% in 2022, then spiked by 125,655bps to 1,065.51% in 2023, then soared by 111,736bps to 2,182.87% in 2024.
- Its last three reported values are 2,182.87% in Q4 2024, 3,079.55% for Q3 2024, and -4,784.91% during Q1 2024.